Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
12:10pm, Wednesday, 05'th Mar 2025
Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 mil
South African watchdog probes Novo Nordisk and Sanofi over insulin
12:14pm, Tuesday, 04'th Mar 2025
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.
Health Rounds: Experimental Sanofi drug delays heart valve disease progression, and potentially surgery
10:14am, Wednesday, 26'th Feb 2025
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, resea
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
01:00am, Tuesday, 25'th Feb 2025
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
02:30am, Saturday, 22'nd Feb 2025
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug
New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on cli
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
07:19am, Wednesday, 19'th Feb 2025
Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi i
Press Release: Sanofi and CD&R sign Opella share purchase agreement
01:30am, Wednesday, 19'th Feb 2025
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed th
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
08:41am, Tuesday, 18'th Feb 2025
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Alnylam: Waiting For Regulatory Updates In March
05:01pm, Thursday, 13'th Feb 2025
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchi
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
02:09pm, Thursday, 13'th Feb 2025
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
01:00am, Thursday, 13'th Feb 2025
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ef
Healthcare company Sanofi announces share buyback of up to 2 billion euros
01:13am, Friday, 07'th Feb 2025
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
Press Release: Execution of a share buyback agreement for up to €2 billion
01:00am, Friday, 07'th Feb 2025
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, p
MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to F
